Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 85 of 5804
-
New drug combo aims to keep stage III lung cancer in check
Disease control Recruiting nowThis is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable …
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New combo targets Hard-to-Treat breast cancer
Disease control OngoingStudy LAE205INT3101 is a Phase Ib/III study to evaluate the efficacy and safety of the combination therapy with afuresertib plus fulvestrant (afuresertib/placebo plus fulvestrant in Phase III) in patients with HR+/HER2- breast cancer who have failed 1 to 2 prior lines of endocrin…
Phase: PHASE3 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Breakthrough trial aims to prevent arthritis in psoriasis patients
Prevention Recruiting nowThis is a multi-center (North-America), randomized, double-blind, placebo-controlled, wait-list, interventional, preventive trial of guselkumab in high-risk psoriasis patients compared to non-biologic standard of care. The primary objective of the proposed trial will be to test …
Phase: PHASE4 • Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:02 UTC
-
Could this IV drug tame lupus kidney flares?
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Simple malaria doses during baby shots could save thousands of lives
Prevention CompletedAs efforts to control malaria are stalling, and the disease is particularly severe in children under the age of two, it is imperative for countries in sub-Saharan Africa, with areas of moderate-to-high transmissions, to implement Perennial Malaria Chemoprevention (PMC) delivered …
Sponsor: Barcelona Institute for Global Health • Aim: Prevention
Last updated Jun 27, 2026 08:14 UTC
-
New hope for hunter syndrome: Brain-Targeting drug in final testing
Disease control OngoingA Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Phase: PHASE3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Chikungunya vaccine shows promise for teens in landmark trial
⭐️ VACCINE ⭐️ CompletedThis was a prospective, randomized, double-blinded, multicenter, pivotal study evaluating the full dose of VLA1553 (1 x10E4 TCID50 per dose) in comparison to a placebo control. The dose of VLA1553 or control was administered as single vaccination on Day 1. Overall, approximately …
Phase: PHASE3 • Sponsor: Butantan Institute • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to cut sickle cell pain crises in half
Disease control OngoingThis clinical trial is a Phase 2/3 study that will determine the recommended dose of mitapivat and evaluate the efficacy and safety of mitapivat in sickle cell disease by testing how well mitapivat works compared to placebo to increase the amount of hemoglobin in the blood and to…
Phase: PHASE2, PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy combo aims to stop stomach cancer return after surgery
Disease control OngoingThis multicenter, randomized, double-blind phase III study intends to recruit about 878 patients, including PD-L1 positive 660 patients, who have received radical gastrectomy (R0 resection, D2 or more extended lymphadenectomy) with postoperative pathological stage IIB or III (AJC…
Phase: PHASE3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can calming the immune system save Kids' livers?
Disease control Recruiting nowTReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equ…
Phase: PHASE2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Immunotherapy plus radiation may eliminate rectal cancer before surgery
Disease control OngoingThis phase II trial investigates the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, su…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug cocktail aims to stall lung cancer progression
Disease control OngoingThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unr…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy shows promise in battle against aggressive uterine cancer
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Double-Targeting CAR-T cells aim to outsmart lymphoma relapse
Disease control OngoingCAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, the investigators supposed that CD19/CD22 bispecific CAR-T cell therapy would be more e…
Phase: PHASE2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill aims to help heart patients breathe easier and move more
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) versus placebo in adults with symptomatic hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction.
Phase: PHASE3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Gene therapy shows promise for kids with SMA type 2
Disease control CompletedThis was a Phase III multi-center, single dose (1.2 x 10\^14 vector genomes), randomized, sham controlled, double-blind study that investigates the efficacy, safety and tolerability of OAV101B in treatment naive, sitting and never ambulatory SMA patients 2 to \<18 years of age.
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Simple feeding pause could save preemie lives
Prevention Recruiting nowThe WHEAT International trial is a comparative effectiveness trial exploring whether withholding enteral feeds around the time of blood transfusion in very premature infants (\<30 weeks) will reduce the occurrence of Necrotizing Enterocolitis (NEC). Currently both continued feedi…
Phase: NA • Sponsor: IWK Health Centre • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control OngoingThis is an open, single-arm, dose-escalation and multiple-dose study to evaluate the safety, tolerability and preliminary effectiveness of B7-H3-targeting Chimeric Antigen Receptor-T (CAR-T) cell therapy on patients with recurrent glioblastomas. The study also plan to explore the…
Phase: PHASE1 • Sponsor: Beijing Tiantan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can a short burst of radiation plus triple chemotherapy wipe out rectal cancer before surgery?
⭐️ CURE ⭐️ OngoingThe aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
Phase: PHASE2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New hope for lung cancer patients who stop responding to targeted drugs
Disease control OngoingA Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor …
Phase: PHASE3 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC